Back to List View Graph View

Belimumab

Belimumab is a biologic therapy used in systemic lupus erythematosus (SLE).

Where the papers sit

14 papers from the last 6 months study belimumab directly · updated from PubMed 5 Nov 2026

  • Systemic Lupus Disease Control

    Belimumab is being positioned as a steroid-sparing treatment that supports sustained disease control in systemic lupus erythematosus. Remission and LLDAS analyses emphasize targets that exclude glucocorticoid exposure, while tapering studies examine flare risk during prednisone reduction. Benefits are explored across thrombocytopenia, pulmonary arterial hypertension, and prevention of long-term organ damage. Long-term safety and consistent disease-activity domains remain central to judging its value.

    8 papers · 57.1%

  • Renal Response in Lupus Nephritis

    Renal response is the central goal, with real-world studies assessing deep and complete responses to belimumab in lupus nephritis. Baseline peripheral-blood CD19+ B-cell proportions may help identify patients likely to respond early. Hematuria, biopsy findings, and follow-up measures recur as markers of renal improvement and durability. Clinical guidance is moving toward standardized definitions of response and closer integration of biomarkers with treatment decisions.

    3 papers · 21.4%

  • Real-World SLE Treatment

    Real-world practice is evaluating belimumab for refractory systemic lupus erythematosus, with registries and cohorts tracking disease activity and treatment effectiveness. Prednisone use and lupus nephritis appear as important clinical contexts rather than isolated outcomes. Anti-dsDNA and other serological markers are being tested for how well they reflect activity during treatment. The main direction is toward integrating routine clinical and laboratory data, although the evidence remains observational.

    3 papers · 21.4%

NEW DIRECTION

Belimumab changes how serological markers can be used to monitor SLE activity

The systemic lupus erythematosus cohort in the BELILES-GEAS registry found that, during belimumab treatment, clinical activity and prednisone use decreased while C3, C4 and anti-dsDNA status remained largely stable; low C3 and C4 were not associated with flares, whereas anti-dsDNA positivity was. This challenges treating conventional complement changes as reliable indicators of flare during belimumab therapy and gives belimumab a monitoring-relevant role beyond its use as a treatment, biomarker predictor or disease-activity intervention 42476625Jul.

Papers

The 14 papers from the last 6 months that study belimumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Systemic Lupus Disease Control (8)
  1. Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies. Lupus science & medicine · 5 Oct 2026 PMID 42833728
  2. Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study. Modern rheumatology · 19 Aug 2026 PMID 42616068
  3. Achievement of real-world adapted DORIS remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study. Lupus · 12 Aug 2026 PMID 42583764
  4. Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. RMD open · 3 Jul 2026 PMID 42399079
  5. Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. Modern rheumatology · 26 Jun 2026 PMID 42360362
  6. Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre. Lupus science & medicine · 18 Jun 2026 PMID 42315241
  7. Belimumab induces early and sustained resolution of lupus thrombocytopenia. Lupus science & medicine · 17 Jun 2026 PMID 42309555
  8. Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. Lupus science & medicine · 21 May 2026 PMID 42167880
Renal Response in Lupus Nephritis (3)
  1. Deep clinical renal response in lupus nephritis treated with belimumab: a real-world cohort study. Rheumatology (Oxford, England) · 20 Oct 2026 PMID 42900520
  2. Peripheral blood CD19+B cell proportion at baseline predicts early complete response to belimumab treatment in patients with refractory lupus nephritis. Lupus science & medicine · 3 Aug 2026 PMID 42547265
  3. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. American journal of kidney diseases : the official journal of the National Kidney Foundation · 21 Jul 2026 PMID 42481080
Real-World SLE Treatment (3)
  1. Effectiveness of belimumab in reducing disease activity in patients with refractory systemic lupus erythematosus: Real-world evidence. Medicina clinica · 21 Aug 2026 PMID 42628281
  2. Impact of belimumab on the utility of serological markers for assessing systemic lupus erythematosus activity. Lupus science & medicine · 20 Jul 2026 PMID 42476625
  3. Spanish multicenter registry of belimumab in systemic lupus erythematosus: Data from daily clinical practice. Seminars in arthritis and rheumatism · 10 Jun 2026 PMID 42269227

By study type

Clinical trials (2)
  1. Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. RMD open · 3 Jul 2026 PMID 42399079
  2. Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. Lupus science & medicine · 21 May 2026 PMID 42167880
Observational studies and case reports (5)
  1. Achievement of real-world adapted DORIS remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study. Lupus · 12 Aug 2026 PMID 42583764
  2. Peripheral blood CD19+B cell proportion at baseline predicts early complete response to belimumab treatment in patients with refractory lupus nephritis. Lupus science & medicine · 3 Aug 2026 PMID 42547265
  3. Impact of belimumab on the utility of serological markers for assessing systemic lupus erythematosus activity. Lupus science & medicine · 20 Jul 2026 PMID 42476625
  4. Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study. Modern rheumatology · 26 Jun 2026 PMID 42360362
  5. Spanish multicenter registry of belimumab in systemic lupus erythematosus: Data from daily clinical practice. Seminars in arthritis and rheumatism · 10 Jun 2026 PMID 42269227
Human data, design not indexed (5)
  1. Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies. Lupus science & medicine · 5 Oct 2026 PMID 42833728
  2. Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study. Modern rheumatology · 19 Aug 2026 PMID 42616068
  3. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. American journal of kidney diseases : the official journal of the National Kidney Foundation · 21 Jul 2026 PMID 42481080
  4. Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre. Lupus science & medicine · 18 Jun 2026 PMID 42315241
  5. Belimumab induces early and sustained resolution of lupus thrombocytopenia. Lupus science & medicine · 17 Jun 2026 PMID 42309555
Unclassified: not yet indexed with MeSH (2)
  1. Deep clinical renal response in lupus nephritis treated with belimumab: a real-world cohort study. Rheumatology (Oxford, England) · 20 Oct 2026 PMID 42900520
  2. Effectiveness of belimumab in reducing disease activity in patients with refractory systemic lupus erythematosus: Real-world evidence. Medicina clinica · 21 Aug 2026 PMID 42628281